Pfizer plans to shutter one vax plant, beef up another

Pfizer (NYSE: PFE) isn't just cutting manufacturing ops in the wake of its merger with Wyeth. The pharma giant is actually adding to its staff at its facility in Lincoln, NE, which develops and manufactures animal vaccines.

Pfizer says it plans to hire about 60 new workers to add to the force of 415 employees that had been expected to be on the manufacturing payroll at the end of this year. Another 70 workers are engaged in R&D at the site. A Pfizer spokesman says that the company has invested $100 million in the operation over the past several years.

Nebraska's gain, meanwhile, comes with a big loss in the Netherlands. Pfizer is winding down its animal vaccine facility in that country, with plans to lay off 110 workers over the next 18 months to two years.

"As part of the Plant Network Strategic Review, today's announcement represents the results of that review," Pfizer spokesman Rick Chambers tells the Kalamazoo Gazette. "We are finished with the Plant Network Strategic Review of the Animal Health network. Of course, we still continue to look at our operations worldwide and make changes where needed."

- here's the story from the Lincoln Journal Star
- and here's the report from the Kalamazoo Gazette

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.